Endocrine therapy
Adherence to endocrine therapy among Chinese patients with breast cancer: current status and recommendations for improvement
... of endocrine therapy decreased recurrence and death by 28% and 15%, respec- tively (Table ...adjuvant endocrine therapy (Figure 2A; HR ...
11
MMP7 expression regulated by endocrine therapy in ERβ-positive colon cancer cells
... Endocrine therapy of colorectal carcinoma has been sug- gested for decades, and there is some evidence to support its use on colon cancer. Epidemiological data and gender differences in the incidence of ...
8
Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer
... that endocrine therapy is not warranted in these ...starting therapy, despite the findings from previous investigators ...with therapy. In our sample, patient attitudes about endocrine ...
9
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers
... A further limitation of current clinical studies is the use of pooled data analysis obtained from large heterogeneous groups of patients. Even if clinical studies are performed using specific patient subgroups, such as ...
10
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
... treatment. Endocrine therapy is the mainstay of treatment for advanced prostate ...deprivation therapy (ADT) at some stage after diagnosis (Meng et al, 2002) and men remain on such treatment for up ...
5
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer
... Paired breast cancer specimens from both baseline core needle biopsy and post-treatment surgery or follow- up core needle biopsy after primary endocrine therapy were collected from each patient for ...
15
Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
... There were several limitations in this study. First, the sample size was small because of the restricted number of samples for RS. In particular, the combined anal- ysis required matching samples between pretreatment and ...
7
Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
... Adjuvant endocrine therapy; AI: Aromatase inhibitor; BMQ: Beliefs about Medicines Questionnaire; CES-D: Center for Epidemiological Studies- Depression Scale; CFI: Comparative fit index; CT: Chemotherapy; ...
8
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy
... in endocrine therapy-resistant breast cancer cell lines have revealed a miR-222- CDKN1B /p27 Kip1 expression network that is conserved in both tamoxi- fen-resistant and fulvestrant-resistant MCF-7 cells ...
19
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
... diameter and nodal status. To smooth single- year irregularities in Kaplan–Meier analyses, for some subgroups we estimated the event rate in a particular time period as the rate (first event per patient-year) for that ...
11
Patient experience of taking adjuvant endocrine therapy for breast cancer: a tough pill to swallow
... Adjuvant endocrine therapy (AET) has substantially improved the mortality rate among breast cancer survivors. Despite the proven efficacy, the non-adherence rate to therapy is still high. This study ...
13
miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer
... Overexpression of miR-190 led to a significant inhibition of mammosphere formation (Fig. 4f ) and a significant re- duction in the percentage of CD44 high /CD24 low cancer stem cell (CSC) population (Fig. 4g). With ...
13
Case Report A case of breast primary neuroendocrine carcinoma treated with neoadjuvant endocrine therapy
... neoadjuvant endocrine therapy with goserelin and ...adjuvant endocrine therapy to treat breast primary neuroendocrine ...neoadjuvant endocrine therapy was demonstrated for ...
5
Efficacy of brachytherapy combined with endocrine therapy and external beam radiotherapy in the treatment of intermediate
... risk levels. Low-risk PCa patients can be treated with radical prostatectomy, internal radiotherapy alone, external beam radiotherapy (EBRT) and ac- tive monitoring [3,4]. According to the EAU Guide- lines on Prostate ...
7
Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence
... Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in reducing the risk of recurrence and mortality after treatment for primary breast cancer[r] ...
10
"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
... of endocrine agents in first 5 lines of therapy is shown in Table ...other endocrine agents is shown in Table ...line endocrine therapy as shown in Table ...crine therapy went ...
7
Oncology providers’ perspectives on endocrine therapy prescribing and management
... Purpose: Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with hormone receptor-positive breast cancer. Overall, initiation and adherence to ET are suboptimal, though reasons ...
13
Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
... Rutqvist [13] has reported but not fully published results from the Zoladex in Premenopausal Patients trial – a large randomized 2 × 2 factorial study in which premenopausal women with early-stage disease were randomly ...
7
Endocrine therapy for breast cancer: a model of hormonal manipulation
... cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to ...established endocrine therapies to maximise ...of endocrine therapy in breast ...
16
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
... received endocrine therapy alone and in those who received chemo- therapy plus endocrine ...receiving endocrine therapy alone, irrespective of node-positivity of the ...plus ...
10